MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Corcept Therapeutics Inc

Suletud

SektorTervishoid

71.88 -0.15

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

71.36

Max

72.15

Põhinäitajad

By Trading Economics

Sissetulek

-9.8M

21M

Müük

-25M

157M

P/E

Sektori keskmine

58.735

39.564

Aktsiakasum

0.169

Kasumimarginaal

13.069

Töötajad

500

EBITDA

-22M

3.4M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+73.21% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

28. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-49M

7.7B

Eelmine avamishind

72.03

Eelmine sulgemishind

71.88

Uudiste sentiment

By Acuity

59%

41%

309 / 376 Pingereas Healthcare

Corcept Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. juuli 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FCC Approves U.S. Cellular Sale to T-Mobile

11. juuli 2025, 17:28 UTC

Suurimad hinnamuutused turgudel

SharpLink Gaming Gains on Ethereum Purchase

11. juuli 2025, 16:57 UTC

Tulu

BASF Cuts Outlook on Global Economy Uncertainty

12. juuli 2025, 17:01 UTC

Tulu

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12. juuli 2025, 14:53 UTC

Tulu

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12. juuli 2025, 02:24 UTC

Omandamised, ülevõtmised, äriostud

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12. juuli 2025, 02:05 UTC

Omandamised, ülevõtmised, äriostud

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12. juuli 2025, 02:05 UTC

Omandamised, ülevõtmised, äriostud

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12. juuli 2025, 02:05 UTC

Omandamised, ülevõtmised, äriostud

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11. juuli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. juuli 2025, 19:46 UTC

Omandamised, ülevõtmised, äriostud

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. juuli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. juuli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. juuli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. juuli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. juuli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. juuli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. juuli 2025, 16:42 UTC

Tulu

BASF Cuts Outlook on Global Economic Uncertainty

11. juuli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. juuli 2025, 16:05 UTC

Tulu

BASF Will Publish Half-Year Results on July 30

11. juuli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. juuli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. juuli 2025, 16:03 UTC

Tulu

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. juuli 2025, 16:02 UTC

Tulu

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. juuli 2025, 16:01 UTC

Tulu

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. juuli 2025, 16:00 UTC

Tulu

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. juuli 2025, 15:59 UTC

Tulu

BASF Cuts 2025 Earnings View

11. juuli 2025, 15:58 UTC

Tulu

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. juuli 2025, 15:57 UTC

Tulu

BASF 2Q EBIT Before Special Items EUR810M

11. juuli 2025, 15:54 UTC

Tulu

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Võrdlus sarnastega

Hinnamuutus

Corcept Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

73.21% tõus

12 kuu keskmine prognoos

Keskmine 124.5 USD  73.21%

Kõrge 145 USD

Madal 80 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Corcept Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

309 / 376 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.